Overview

Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
There are three elements to this study: - Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. - Part B: Single dose escalation in patients with mild/moderate COPD. 3 dose levels of QAK423 are planned in COPD patients. - Part C: Titrated repeat dosing for a maximum of 14 days in mild/moderate COPD patients. Repeat dosing is planned in COPD patients.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals